- Stocks
- Pharma & Healthcare
- Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company share price
NSE: SPARCPharma & HealthcareDrug Manufacturers - Specialty & Generic
Sun Pharma Advanced Research Company at a glance
Sun Pharma Advanced Research Company (NSE: SPARC) closed at ₹176.82 on 22 Oct 2026, down 1.22% on the day. With a market capitalisation of ₹5,738 Cr, it ranks 736th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 3.7× trailing earnings, against a return on equity of 116.0% in FY26. Over the past year the share price has risen 35.4%. Its 52-week range is ₹108.00 (23 Mar 2026) to ₹289.00 (8 Jul 2026); the last close is 38.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹13 Cr (−51.5% year on year) and net profit ₹1,761 Cr, on a consolidated basis. Promoters held 65.67% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹5,738 CrRank 736 on NSE
- P/E (trailing)
- 3.7×
- Price to book
- 2.78×FY26
- EPS (TTM)
- ₹47.85to Q4 FY26
- ROE
- 116.0%FY26
- ROCE
- 112.9%FY26
- Debt to equity
- 0.42FY26
- Net profit margin
- 82.7%FY26
- Book value / share
- ₹41.26FY26
- 52-week high
- ₹289.008 Jul 2026
- 52-week low
- ₹108.0023 Mar 2026
- 1-year return
- +35.4%
- RSI (14-day)
- 35.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.22% | −8.3% | −10.3% | −17.3% | +35.4% |
Sun Pharma Advanced Research Company quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹17 Cr | ₹13 Cr | ₹15 Cr | ₹27 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹13 Cr |
| Revenue YoY | −29.8% | −39.3% | +7.6% | +64.2% | −42.7% | −38.9% | −43.3% | −51.5% |
| Net profit | −₹96 Cr | −₹107 Cr | −₹80 Cr | −₹60 Cr | −₹52 Cr | −₹76 Cr | −₹80 Cr | ₹1,761 Cr |
| Net profit YoY | — | — | — | — | — | — | — | — |
| Net margin | −570.5% | −834.6% | −533.3% | −219.8% | −538.1% | −965.0% | −951.7% | 13,343.5% |
| EPS | −₹2.96 | −₹3.31 | −₹2.45 | −₹1.84 | −₹1.60 | −₹2.34 | −₹2.48 | ₹54.27 |
Sun Pharma Advanced Research Company financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹239 Cr | ₹76 Cr | ₹72 Cr | — |
| Operating profit | −₹223 Cr | −₹387 Cr | −₹343 Cr | — |
| Net profit | −₹223 Cr | −₹387 Cr | −₹343 Cr | — |
| EPS (₹) | −₹8.00 | −₹12.00 | −₹11.00 | — |
| Cash from operations | −₹69 Cr | −₹429 Cr | −₹360 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹100 Cr | ₹0 Cr |
| Shareholders' equity | ₹513 Cr | ₹126 Cr | −₹217 Cr | ₹1,339 Cr |
Sun Pharma Advanced Research Company shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 22 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
| Foreign institutions | 1.47% | 1.76% | 2.04% | 2.04% | 2.47% | 3.90% |
| Domestic institutions | 0.97% | 1.05% | 0.78% | 0.88% | 0.10% | 0.09% |
| Non-institutions | 31.88% | 31.52% | 31.51% | 31.41% | 31.76% | 30.33% |
Sun Pharma Advanced Research Company vs peers
The listed Pharma & Healthcare companies nearest to Sun Pharma Advanced Research Company by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
| SPARCSun Pharma Advanced Research Company | ₹176.82 | −1.22% | +35.4% | ₹5,738 Cr | 3.7 | — |
| SENORESSenores Pharmaceuticals | ₹1,233.30 | +0.35% | +71.0% | ₹5,680 Cr | 46.7 | — |
| INNOVACAPInnova Captab | ₹983.60 | +0.57% | +17.9% | ₹5,629 Cr | 40 | — |
| FDCFDC | ₹339.20 | −0.24% | −22.1% | ₹5,523 Cr | — | — |
| IOLCPIOL Chemicals and Pharmaceuticals | ₹173.27 | −0.76% | +80.5% | ₹5,086 Cr | 36.9 | — |
Ask anything about Sun Pharma Advanced Research Company
Pivot answers on the live chart with evidence you can check, and tests strategies against SPARC's own history. Try: “Why has SPARC moved over the last three months?” · “Backtest a 50-day moving-average crossover on SPARC over five years” · “Compare SPARC with KOVAI on margins and valuation”
Frequently asked questions about Sun Pharma Advanced Research Company
What is the share price of Sun Pharma Advanced Research Company today?
Sun Pharma Advanced Research Company (NSE: SPARC) last closed at ₹176.82 on 22 Oct 2026. Its 52-week high is ₹289.00 and its 52-week low is ₹108.00.
What is the market cap of Sun Pharma Advanced Research Company?
Sun Pharma Advanced Research Company's market capitalisation is ₹5,738 Cr (₹5,738 Cr) at the 22 Oct 2026 close, ranking 736th among the NSE companies Pivot tracks.
What is the P/E ratio of Sun Pharma Advanced Research Company?
Sun Pharma Advanced Research Company trades at a trailing P/E of 3.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.
What is the ROE and ROCE of Sun Pharma Advanced Research Company?
Return on equity was 116.0% in FY26 and return on capital employed was 112.9% in FY26 (consolidated figures).
Is Sun Pharma Advanced Research Company a debt-free company?
No. Sun Pharma Advanced Research Company's debt-to-equity ratio was 0.42 in FY26, with total debt of ₹0 Cr.
What were Sun Pharma Advanced Research Company's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Sun Pharma Advanced Research Company reported revenue of ₹13 Cr, −51.5% year on year, and net profit of ₹1,761 Cr.
How has Sun Pharma Advanced Research Company stock performed over the last year?
Sun Pharma Advanced Research Company's share price has risen 35.4% over the past year, −17.3% over three months and −10.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Sun Pharma Advanced Research Company?
As of 30 Jun 2026: promoters 65.67%, foreign institutions 3.90%, domestic institutions 0.09%, non-institutions 30.33%.
Who are Sun Pharma Advanced Research Company's competitors?
The listed Pharma & Healthcare companies closest to Sun Pharma Advanced Research Company by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Senores Pharmaceuticals, Innova Captab, FDC and IOL Chemicals and Pharmaceuticals.
Is Sun Pharma Advanced Research Company a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sun Pharma Advanced Research Company's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SPARC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text